Skip to main content

Table 2 Dose-effect relationships of isomorellin, forbesione and doxorubicin combinations in cholangiocarcinoma cell lines

From: Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

Cell line Single compounds, drug & combinations Parameter CI value DRI value
   r IC50 IC75 IC90 IC50 IC75 IC90
KKU-M156 Isomorellin 0.86     29.65 53.54 96.69
Doxorubicin 0.91     1.12 2.18 4.23
(D)1 + (D)2 (1 : 1.25) 0.97 0.92 0.47 0.24    
KKU-100 Forbesione 0.88     4.46 8.32 15.51
Doxorubicin 0.88     1.00 1.73 2.99
(D)1 + (D)2 (1 : 0.25) 0.98 1.21 0.69 0.39    
KKU-M139 Isomorellin 0.93     2.15 1.89 1.66
Doxorubicin 0.94     3.04 2.57 2.17
(D)1 + (D)2 (2 : 1) 0.81 0.80 0.92 1.06    
Forbesione 0.89     3.28 2.83 2.44
Doxorubicin 0.89     6.57 5.20 4.12
  (D)1 + (D)2 (2 : 1) 0.85 0.46 0.55 0.65    
  1. Dose-effect relationships calculated using the median-effect equation. The r linear correlation is the coefficient of the median effect plot (indicates conformity of data). CIs were calculated using Chou and Talalay’s CI equation. The DRI dose reduction index was measured by comparing doses required to reach a given degree of inhibition when using compound(s) or drug as a single agent and/or in combination.